Skip to content
Screener

Capricor Therapeutics CAPR Retained Earnings

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.55B-2.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.97B-6.7%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$1.97B-18.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$1.52B-42.4%
Cytokinetics logo
CytokineticsCYTK
-$3.89B-29.8%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$222.96M-46.2%
Enterprise value$132.32M-66.3%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Line itemMarch 31, 2026 / (unaudited)December 31, 2025December 31, 2025
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 57,664,673 and 57,370,909 shares issued and outstanding, respectively57,66557,371
Additional paid-in capital617,718,525610,330,105
Accumulated other comprehensive income(253,727)283,154
Accumulated deficit(338,819,830)(304,878,485)
TOTAL STOCKHOLDERS’ EQUITY278,702,633305,792,145
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$326,283,517$$355,949,294

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's retained earnings?
Capricor Therapeutics (CAPR) reported retained earnings of -$338.82M in Q1 2026.
How has Capricor Therapeutics's retained earnings changed year-over-year?
Capricor Therapeutics's retained earnings decreased by 51.1% year-over-year, from -$224.23M to -$338.82M.
What is the long-term trend for Capricor Therapeutics's retained earnings?
Over 5 years (2020 to 2025), Capricor Therapeutics's retained earnings has grown at a 28.2% compound annual growth rate (CAGR), from -$88.04M to -$304.88M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Capricor Therapeutics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude